Introduction {#S0001}
============

Chronic kidney disease (CKD) is common and continues to rise universally. ‎It is a risk factor for end-stage renal disease (ESRD) and is also a strong risk ‎factor for cardiovascular disease (CVD) and mortality.[@CIT0001] ESRD is a complex ‎disorder with a variety of phenotypes starting from a diversity of underlying ‎disorders of the kidney in conjunction with genetic and environmental factors in ‎addition to other preexisting or secondary clinical entities.[@CIT0002]

Renin-angiotensin--system (RAS) is a multifunctional system. A number of ‎genetic variations linking RAS components have clinical or physiological ‎influences. Among the candidate genes of RAS, the angiotensin-converting ‎enzyme (ACE), angiotensinogen (AGT) and angiotensin II type 1 receptor‎‎ (AGTR1) genes which appear to be mainly biologically and clinically relevant to renal ‎disease. The genetic polymorphisms of these key components of RAS provide a ‎basis for studying the relationship between genetic variants and the development ‎of CVD and/or renal damage.[@CIT0003]

Despite the enormous number of studies looking for candidate genes, the ACE ‎gene stills the unique, well-characterized locus that clearly associated with ‎pathogenesis and progression of CKD.[@CIT0004] ACE gene polymorphism (rs1799752) ‎characterized by the deletion (D) or insertion (I) of a 287 base pair (bp) ‎fragment in the 17q23 chromosome was identified in 1990.[@CIT0005]

Angiotensin II stimulates the proliferation of early erythroid progenitors in-vitro. ‎Consequently, ACE DD carriers may exhibit greater erythropoietic activity. ‎Some researchers reported an elevation in erythropoietin (EPO) requirement in ‎patients with the ACE II genotype undergoing peritoneal dialysis, but others ‎found no effect.[@CIT0006]

Hence, this study was designed to evaluate the frequencies of ACE gene ‎polymorphism in Iraqi patient with CKD on maintenance hemodialysis, ‎compare them with a group of healthy subjects, and to examine the association ‎between this polymorphism and serum EPO and hemoglobin (Hb) levels.‎‎

‎

Materials and methods {#S0002}
=====================

This study was conducted at Medical City Complex, Baghdad Teaching ‎Hospital, Iraqi center of kidney dialysis from November 2015 until June 2016. ‎The study protocol approved by the committee of local ethics in the college of ‎medicine, University of Baghdad, Iraq with written informed consent taken from ‎the participants, ‎and the study and all its procedure were done by the Helsinki Declaration of 1975, ‎as revised in 2000.‎

Those who satisfied the following criteria participated in this study: (1) ‎treatment with hemodialysis for at least six months; (2) age \>18 years; and (3) ‎receiving injections of methoxy polyethylene glycol epoetin-beta (MPGE-β) for ‎renal anemia. Exclusion criteria were: (1) recent symptoms and signs of bleeding ‎that required a blood transfusion; (2) acute renal failure; (3) malignant disease; ‎‎(4) hematologic disease; and (5) acute infectious disease.‎

Those who completed the study courses successfully were grouped into: ‎

**Patients Group**: Includes 70 CKD patients (40 males and 30 females).‎

**Control Group**: Includes 20 healthy subjects (10 males and ten females) without ‎any medical problems.‎

Three milliliters of venous blood samples were collected in the morning after an ‎overnight fast before the dialysis session. Serums were extracted from two ml of ‎blood sample while the remaining one ml was collected in EDTA vials for the ‎extraction of genomic DNA. Samples were collected from each patient at the ‎beginning of the study (baseline sample), and then after three months and after six ‎months from the baseline sample to follow-up the changes in the studied ‎parameters. Samples then were stored at (--80 C) until the time of the assay. A single ‎blood sample drawn from each subject of the control group for comparison.‎

The dose of MPGE-β was titrated by 25% every two weeks in an attempt to ‎maintain a target Hb level between 10 and 11 g/dl, and serum EPO ‎concentrations measured by ELISA (using DEMEDITEC EPO ‎immunoassay, Germany).‎

According to the manufacturer's protocol, genomic DNA extracted from ‎blood samples (baseline samples only) by using genomic DNA extraction kit ‎, and the quality of DNA was analyzed by agarose gel electrophoresis.‎

The ACE gene polymorphism was detected by polymerase chain reaction (PCR) ‎according to the method described by Mattu et al[@CIT0007] with some modification. The ‎template genomic DNA (0.5 μg per sample) was amplified using the following ‎primers: ‎

‎Forward: 5'CTG GAG ACC ACT CCC ATC CTT TCT 3' ‎

‎Reverse: 5' GAT GTG GCC ATC ACA TTC GTC AGA T 3' ‎

These primers (10 pmol of each) were added to a mixture containing 10 mmol/L ‎Tris-HCl (pH 9.0); 30 mmol/L KCl; 250 μmol/L dNTP (each of dATP, dCTP, ‎dGTP, and dTTP); 1.5 mmol/L MgCl2; and 1 U Taq DNA polymerase in a final ‎volume of 20 μL. ‎

The PCR was initiated with a denaturation by first heating the samples for 3 ‎minutes at 95 °C. Thirty-five cycles of denaturation for 30 seconds at 95 °C, ‎annealing for 30 seconds at 58 °C, primer extension for 30 seconds at 72 °C, and ‎the last extension for 5 mins at 72 °C applied for amplification. The PCR ‎products of the ACE gene locus (The 490 bp in case of insertion and 190 bp in ‎case of deletion products) were run on 2% agarose gel electrophoresis at 150 V ‎for 60 min and visualized at room temperature under UV light after ethidium ‎bromide (0.5 μg/mL) staining. ‎

Statistical calculations were made using the SPSS program version 20, and ‎Minitab version 17 software. A -value\<0.05 was considered statistically ‎significant in all comparisons. Anderson Darling test was made to check the ‎adherence of continuous variables to a normal distribution. Discrete variables were ‎presented using their number and percentages. The chi-square test used for ‎comparisons of discrete variables between each study group. Genotypes ‎frequencies of the ACE gene obtained by direct count. Linear regression ‎analysis was made to assess the relationship between serum EPO and Hb.

Results {#S0003}
=======

Demographic and laboratory data of this study groups are expressed in [Table 1](#T0001){ref-type="table"}. ‎The PCR product of ACE gene polymorphism is schematized in [Figure 1](#F0001){ref-type="fig"}. The ‎distribution of ACE genotypes and their alleles between the study groups is ‎similar (*p*-value\>0.05), so no differences in distribution between CKD patients and ‎healthy subject as presented in [Tables 2](#T0002){ref-type="table"} and [3](#T0003){ref-type="table"}.‎Table 1Demographic data of the study groups at a baseline levelVariablesControl (n=20)Patient (n=70)*p*-valueAge (years)\*46.2±6.349.3±7.40.071^a^BMI (kg/m^2^)\*25.45±4.9527.72±5.170.331^a^Pulse rate (beat/min)\*77.95±9.9077.05±13.020.777^a^Hemoglobin (g/dl)\*14.26±1.188.23±1.41\<0.001^a^Serum erythropoietin (mIU/ml)†7.655 (3.963--9.523)3.355 (2.1--5.463)0.001^b^[^1] Table 2Distribution of *ACE* gene polymorphism in the study groupsGeneGenotypesControl (n) %Patient (n) %*p*-value*ACE*DD(4) 20.0%(26) 37.1%0.33II(4) 20.0%(9) 12.9%ID(12) 60.0%(35) 50.0%[^2] Table 3Distribution of individual *ACE* gene alleles in the study groupsGeneGroupsD allele (n) %I allele (n) %*p*-value*ACE*Patient(87) 62.15%(53) 37.85%0.168Control(20) 50.0%(20) 50.0%[^3] Figure 1A 2% agarose gel electrophoresis of PCR product demonstrating ACE ‎gene polymorphism. Lane M: 100 bp DNA Ladder (100--1,500 bp). Lane 2: II ‎homozygote alleles (band at 490 bp). Lanes 1, 4, and 6: DD homozygote alleles (bands ‎at 190 bp). Lanes 3, 5, 7, and 8: ID heterozygote alleles (bands at 190 bp and 490 bp).

The prevalence of ACE genotypes in the patients group is varied in which ID ‎genotype is the most common (50%), followed by DD genotype (37%) and II ‎genotypes (13%). ‎

As shown in [Table 4](#T0004){ref-type="table"}, the control group had a nonsignificant difference in serum ‎EPO levels among different ACE genotypes (*p*-value\>0.05), as well as, in patients ‎group all different ACE genotypes had nonsignificant differences in serum EPO ‎levels at all periods. According to individual ACE genotypes, patients with ‎ID genotype displayed a more significant (*p*-value\<0.05) elevation in serum EPO ‎levels with time, followed by DD genotype, while II genotype had a nonsignificant elevation.‎ Table 4Serum erythropoietin levels (mIU/ml) divided by ACE genotypes. Data expressed as median (IQR)GroupsDDIDII*p*-value^a^Control baseline4.13 (3.24--7.07)7.65 (4.22--9.49)9.32 (5.19--13.52)0.175Patient baseline3.45 (2.35--9.47)3.09 (1.62--5.32)2.71 (1.75--4.35)0.161Patient 3 months5.07 (2.68--8.23)4.8 (2.1--10.3)4.6 (1.55--13.35)0.785Patient 6 months15.38 (6.57--24.1)7.29 (5.01--17.63)7.14 (3.87--14.91)0.129*P*-value^b^0.00020.00010.097[^4]

As shown in [Table 5](#T0005){ref-type="table"}, nonsignificant differences (*p*-value\>0.05) in Hb levels were ‎observed for control and patients groups among different ACE genotypes. ‎According to individual ACE genotypes, patients with different ACE genotypes ‎exhibited a nonsignificant change in Hb levels with the time.‎ Table 5Hb levels (g/dl) divided by ACE gene polymorphism. Data expressed as mean ± SDGroupsDDIDII*p*-value^a^Control baseline13.88±1.3214.18±0.8414.9±1.910.458Patient baseline8.33±1.398.26±1.487.81±1.170.625Patient 3 months8.71±1.529.01±1.648.03±1.100.218Patient 6 months8.38±1.408.52±1.738.01±1.030.666*P*-value^b^0.5800.1480.895[^5]

Results presented in [Table 6](#T0006){ref-type="table"} and [Figure 2](#F0002){ref-type="fig"} showed that the overall correlation ‎between EPO and Hb in the control group was significant (*p-*value\<0.05) and moderately ‎positive. However, different ACE genotype groups showed a nonsignificant ‎correlation, despite the high correlation coefficient for DD and II polymorphism this can be attributed to low number of subjects had DD (4 subjects) and II (4 subjects) polymorphism in control group. Table 6Correlation between serum erythropoietin and Hb levels in the control group for each ACE genotype at baselineACE genotypesCorrelation coefficient*p*-valueOverall0.6120.004DD0.8780.122II0.7420.258ID0.3910.209[^6] Figure 2Scatterplot for control group describing the correlation between serum erythropoietin (EPO) and Hb.

‎ Results presented in [Table 7](#T0007){ref-type="table"} and [Figure 3](#F0003){ref-type="fig"} showed that the overall correlation ‎between EPO and Hb in patients group at baseline was nonsignificant (*p*-value\>0.05) ‎and weakly negative; however, only DD genotype had a mild and significant inverse correlation, while II genotype had a nonsignificant and direct ‎correlation.‎ Table 7Correlation between serum erythropoitinand Hb in patients group for each ACE genotype at baselineACE genotypesCorrelation coefficient*p*-valueOverall−0.2100.080DD−0.4120.037II0.0030.995ID−0.0550.756[^7] Figure 3Scatterplot for patient group describing the correlation between serum erythropoietin (EPO) and Hb at baseline.

Results presented in [Table 8](#T0008){ref-type="table"} showed that the overall correlation ‎between EPO and Hb in patients group at three months interval was nonsignificant ‎‎(*p*-value\>0.05) and weakly negative, and different ACE genotypes had an inverse and ‎nonsignificant correlation. Table 8Correlation between serum erythropoietin and Hb in patient group for each ACE genotype at three months intervalACE genotypesCorrelation coefficient*p*-valueOverall−0.2090.083DD−0.1640.423II−0.0810.836ID−0.2730.112[^8]

Results presented in [Table 9](#T0009){ref-type="table"} showed that the overall correlation ‎between EPO and Hb in patients at six months interval was nonsignificant (*p-*value\>0.05) and weakly negative, and different ACE genotypes had an inverse and ‎nonsignificant correlation.‎ Table 9Correlation between serum erythropoietin and Hb in patient group for each ACE genotype at six months intervalACE genotypesCorrelation coefficient*p*-valueOverall−0.1750.148DD−0.2130.297II−0.1000.798ID−0.1850.288[^9]

Discussion {#S0004}
==========

This study was done in an attempt to provide some evidence of the association ‎between ACE gene polymorphism with serum EPO and Hb in Iraqi patients in ‎view of the high prevalence of CKD. The current study showed that ID ‎genotype was the most frequent, followed by DD and II of total cases of CKD, ‎with nonsignificant difference in these genotypes between CKD and healthy ‎subjects. These results approximately consistent with Kiss et al in Hungary ‎which they found that the frequency of ID, DD, and II in CKD patients were 41.5%, ‎‎38.5% and 20.0% respectively.[@CIT0008] On the other hand, Shanmuganathan et al in ‎an Indian cohort found the frequency of ID, DD and II genotypes in patients ‎with CKD without hypertension to be 6.67%, 80.0%, and 13.33%, respectively ‎and the frequency of ID, DD and II genotypes in patients with CKD with ‎hypertension was 93.33%, 6.67%, and 0.0%, respectively,[@CIT0009] while in a study ‎conducted in an Egyptian CKD pediatric population on maintenance ‎hemodialysis the frequency was 40.91%, 56.82%, and 2.27% for ID, DD and II ‎genotypes respectively.[@CIT0010]

These differences are attributed chiefly to different ethnic population. The direct ‎association between some gene polymorphisms and the diseases remains a ‎controversy among various human ancestries reported. Some earlier studies ‎approved the importance of human genetic variation in complex disease which ‎can cause alleles to occur at a greater frequency in people from specific ‎geographic areas.[@CIT0011]

This study for the first time presents a quantitative analysis of serum EPO, ‎Hb, and ACE gene polymorphism in CKD patients receiving MPGE-β therapy ‎also in normal healthy subjects. The main findings regarding this issue were: (1) a significant elevation in serum EPO levels was observed in CKD patients' ‎with DD and ID genotypes throughout the study (ie, a significant effect of ‎ACE gene polymorphism on serum EPO levels). (2)‎ A significant positive correlation was observed between serum EPO and Hb ‎in normal healthy subjects with different ACE genotypes. This indicates that ‎Hb levels will increase when serum EPO increased. ‎(3) A nonsignificant and negative correlation was observed between serum ‎EPO and Hb in CKD patients with different ACE genotypes throughout the ‎study. This indicates that Hb levels will decrease even though serum EPO ‎increased.

‎ A linear relationship is usually observed between the mass of red blood cells and ‎Hb saturation with oxygen in healthy peoples, while an inverse linear ‎relationship between serum EPO and Hb presents in chronically anemic ‎patients.[@CIT0001] Panjeta et al investigated 562 individual subjects for the correlation ‎between EPO, Hb and/or hematocrit based on the degree of renal insufficiency. ‎A correlation between EPO and Hb and/or hematocrit found in healthy ‎subjects, and EPO is significantly correlated (*p*\<0.0005) with Hb and with ‎hematocrit. The correlation is strong and negative, and the value of EPO ‎increases with the decrease of Hb and/or hematocrit. On the other hand, subjects ‎with a third and fourth degree of renal insufficiency EPO was not in correlation ‎with Hb and hematocrit (*p*\>0.05).[@CIT0012] The use of recombinant human ‎erythropoietin has led to anemia correction and improvement in the quality of life ‎for the majority of CKD patients. Nevertheless, there is considerable variability ‎in patient response, and various factors have been linked to this variation.[@CIT0013] ‎However, even after the exclusion of such factors, some patients continue to ‎express suboptimal response.[@CIT0014]

Conclusions {#S0005}
===========

CKD especially ESRD did not significantly alter the distribution of ACE ‎genotypes. Furthermore, ACE gene polymorphism had a significant effect on ‎serum EPO levels, and patients with DD and ID genotypes exhibited a significant ‎elevation in serum EPO levels with time. On the other hand, ACE gene ‎polymorphism did not have a significant effect on Hb levels in these patients.‎
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[^1]: **Notes:** ^a^Independent 2 sample *t*-test; ^b^Mann-Whitney U test; \*Data expressed as mean ± SD. ^†^Data expressed as median (IQR).

[^2]: **Note:** Chi-square test.

[^3]: **Note:** Chi-square test.

[^4]: **Notes:** ^a^Kruskal-Wallis Test; ^b^Friedman ANOVA.

[^5]: **Notes:** ^a^One-way ANOVA; ^b^Trend ANOVA (among patient group only).

[^6]: **Note:** Linear regression analysis.

[^7]: **Note:** Linear regression analysis.

[^8]: **Note:** Linear regression analysis.

[^9]: **Note:** Linear regression analysis.
